A Patent-Protected Revolutionary Technology that is FDA-Approved for Sale in the USA
S.T. Stent has developed the ArchSinus, a distinctive, temporary stent for chronic sinusitis patients, which is used for sinus implantation following sinus surgery and is expected to completely change the standard treatment for patients. The pioneering device dramatically improves surgery outcomes, prevents inflammation and common complications, and is expected to cause a reduction in the need for revision surgery. The ArchSinus is FDA-approved for marketing and sale and is protected by several strong patents listed in the United States, Europe, Japan, China, Australia, Canada, and Israel.
Endorsement and Investments from Leading Innovation Institutes in Israel and Abroad: Trendlines, the Israel Innovation Authority, and Horizon 2020
S.T. Stent operates within the Trendlines Group—Israel’s leading tech incubator, which invested in the current round with Agriline. Trendlines specializes in med-tech investments and is supported by the Israel Innovation Authority. Moreover, the company received the EU’s prestigious Horizon 2020 grant in 2018.
Proven Efficacy in Clinical Trials, Successful Pilots in Leading Medical Centers Around the World, and Commercialization in the United States
The ArchSinus stent has proven its safety and efficacy in two successful clinical trials, which were carried out in top medical centers in the USA and Israel, including Herzliya Medical Center, Northwestern University, and Lenox Hill Hospital. The excellent clinical results have been published in the prominent medical journal the American Journal of Rhinology and Allergy.
The company is currently completing extensive commercial pilots in prominent medical centers in Israel and the United States, such as Northside Hospital, Duke University, Piedmont Hospital, Mount Sinai, Lenox Hill, and more. Several of these medical centers have already purchased the stent and continue to purchase it with repeat orders.
Major Interest in the Company’s Product from the International Medical Community
The company’s technology has sparked major interest from strategic players in the global medical community, following the ArchSinus’ presentation at the annual American Rhinology Society meeting in 2018 and in the RhinoWorld conference in 2019. Some of the field’s most prominent ENT companies, including J&J, Stryker, and Medtronic are closely following the progress of the company. Finally, Baylor Surgical Hospital in Fort Worth, Texas recently because the S.T. Stent’s first paying and repeat customer.
A Team of Internationally Renowned Experts with Broad Med-Tech Development Experience
At the head of S.T. Stent is a strong team with decades of tech, medical, and scientific experience under their belts, in leading companies in Israel and abroad. The team is led by the founder and CEO, Dr. Joseph Flomenblit, who is a medical stent specialist, developer of numerous patent-protected technologies, and a consultant and project manager to conglomerates such as J&J, Boston Scientific, Medinol, and Rephael. Michael Berman, Board Chairman, is an experienced investor and entrepreneur in the medical development field and is on the board of 10 emerging medical companies. Additionally, the company has scientific advisors from prestigious international medical centers, that are currently leading the ENT field in Israel and abroad.
A Broad International Market in Need of an Effective and Economical Solution
There are tens of millions of sinusitis patients in the United States alone, 500,000 of which undergo sinus surgery annually. Half of these patients will experience recurring symptoms and might even need to undergo revision surgery. 90% of this market is left without a solution, due to existing unsatisfactory technologies that fail to prevent the need for revision surgery. The ArchSinus aids in decreasing common complications post-surgery and the need for revision surgery. Thus, the stent is expected to reduce the costs of healthcare services, for insurance companies, and patients alike. Moreover, S.T. Stent’s technology is expected to be beneficial for alternative uses, such as failed nose surgeries, which have yet to be resolved with a proper solution.